Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

- Thermo Fisher Scientific Inc., (NYSE:TMO) the world leader in serving science, today announced continuing support for The Just Project a national initiative to provide COVID-19 testing to students, faculty and staff across more than 60 historically black colleges and universities (HBCUs) at no cost. A $7.5 million commitment for the 2021-2022 school year will once again provide diagnostic instruments, test kits and related supplies.

HBCU Testing

"A year after we launched The Just Project, COVID-19 cases are increasing again, and testing is critical to ensuring campus safety," said Fred Lowery , senior vice president and president for customer channels at Thermo Fisher Scientific. "Last year HBCUs nationwide administered more than 50,000 tests under the project, and infection rates at participating schools were below 1% with minimal academic disruption. We hope other schools will join the program as we extend it through the 2021-2022 school year."

The Just Project, named after pioneering biologist Ernest Everett Just , has created a nationwide testing infrastructure with the capacity to provide free testing for all 107 HBCUs in the U.S. Currently, eight on-campus labs serve as hubs to process samples for more than 60 participating HBCUs. Testing hubs include Florida A&M University , Hampton University , Howard University College of Medicine, Meharry Medical College , Morehouse School of Medicine , Texas Southern University , Tuskegee University and Xavier University of Louisiana .

"The Just Project has made a significant difference on our campus," said Rashid Mosavin, Ph.D., dean of the College of Pharmacy and Health Sciences, Texas Southern University . "With testing available on our campus as frequently as needed, we were able to welcome our students, faculty and staff back to campus for in-person learning with confidence."

James E.K. Hildreth , M.D., Ph.D., president and CEO of Meharry Medical College said, "We're grateful for Thermo Fisher's continued support of COVID-19 testing across HBCUs to serve a broad reach of their students. Testing is the core component of a robust model in preventing the spread of infectious disease. With these resources and testing components in place, we're able to make data-driven decisions and policies to support the health and safety of our students and community."

Given the focus on recruiting diverse talent, Thermo Fisher has also committed to hiring more than 500 HBCU alumni over three years, reinforcing a commitment to create a more inclusive workplace. Since August of 2020, more than 180 HBCU alumni have joined the company.

For more information on The Just Project, please visit our website .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $35 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-continues-support-for-covid-19-testing-on-historically-black-college-and-university-campuses-301387537.html

SOURCE Thermo Fisher Scientific

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×